Stocktoria
Savara Inc SVRA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2001-06-25
Savara Inc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating income | -$123.5M | -$103.2M | -$60.0M | -$38.8M | -$41.5M |
| Income tax | $0 | $9,000 | — | — | — |
| Net income | -$118.8M | -$95.9M | -$54.7M | -$38.1M | -$43.0M |
| EPS (diluted) | $-0.53 | $-0.48 | $-0.33 | $-0.25 | $-0.32 |
| Operating cash flow | -$101.0M | -$89.1M | -$51.1M | -$34.6M | -$40.1M |
| Free cash flow | -$101.1M | -$89.1M | -$51.4M | -$34.6M | -$40.1M |
| Cash & equivalents | $33.2M | $15.1M | $26.6M | $52.1M | $34.0M |
| Total assets | $253.4M | $212.9M | $177.6M | $139.8M | $176.6M |
| Total liabilities | $50.3M | $41.4M | $37.2M | $32.0M | $32.1M |
| Shareholders' equity | $203.1M | $171.4M | $140.4M | $107.8M | $144.5M |
Source: SEC EDGAR filings · CIK 0001160308 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.